Promontory Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals.
Website: www.phosplatin.com
Company Details
- Employees
- 15
- Founded
- -
- Address
- 1350 Avenue Of The Americas, 23rd Fl, New York,new York 10019,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.promontorytx.com
- HQ
- New York, NEW YORK
Promontory Therapeutics Questions
Promontory Therapeutics's website is http://www.promontorytx.com
Promontory Therapeutics's LinkedIn profile is https://www.linkedin.com/company/promontory-therapeutics
Promontory Therapeutics has
15 employees.
View email and phone details for 15
employees at Promontory Therapeutics.
Promontory Therapeutics's industry is
Biotechnology Research
Promontory Therapeutics's top competitors are
Hifibio Therapeutics,
Tg Therapeutics, Inc.,
Juvena Therapeutics,
Ovid Therapeutics,
Axsome Therapeutics, Inc.,
Ksq Therapeutics, Inc.,
Acrivon Therapeutics, Inc.,
Siolta Therapeutics,
Bluerock Therapeutics,
Click Therapeutics, Inc..
Promontory Therapeutics's categories are Biotechnology Research
Promontory Therapeutics's founding year is 2010
